Hilton expands India presence with new DoubleTree hotel in Bhopal
Upscale full-service hotel brand DoubleTree by Hilton is set to debut in the Indian city of Bhopal to enhance hospitality and growth in Central India.
Expected to open its doors in 2027, the new property is a collaborative venture with Sage Group, a business conglomerate in India.
Sage Group chairman and managing director Sanjeev Agrawal said: 'This partnership reflects our vision of enhancing the hospitality landscape in Bhopal and contributing to the region's growth and development.'
According to Hilton, the upcoming DoubleTree by Hilton Bhopal will feature 229 rooms, making it the largest hotel in the city.
It will have three dining venues, including an all-day dining restaurant, a speciality restaurant, and a lobby lounge.
Hilton stated that the new property features 21,000ft² of event space and an 8,000ft² ballroom, which are suitable for conferences, weddings, and corporate gatherings.
Hilton Asia Pacific development senior vice-president Clarence Tan said: 'DoubleTree by Hilton's expanding footprint – now with 20 trading and pipeline hotels in South Asia – reaffirms Hilton's commitment to delivering warm hospitality and thoughtful service, catering to the dynamic needs of business and leisure travellers in gateway cities.
'The brand's combination of upscale service, thoughtful design and amenities makes it an ideal fit for Bhopal, with significant opportunities for further growth in key cities across India.'
The hotel will be situated 17km from Raja Bhoj Airport and 10km from Bhopal Junction railway station.
The DoubleTree by Hilton in Bhopal will join Hilton's growing portfolio in South Asia, which includes 56 trading and pipeline hotels, alongside recent openings in Gurugram and Kathmandu.
Last year, the DoubleTree by Hilton brand reached a key achievement, exceeding 100 properties across the Asia Pacific region.
DoubleTree by Hilton is an expanding global hotel brand with nearly 700 locations and more than 155,000 rooms, spanning 58 countries and territories.
"Hilton expands India presence with new DoubleTree hotel in Bhopal" was originally created and published by Hotel Management Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
40 minutes ago
- Entrepreneur
Crafting Men's Confidence
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. What began as an ambition to offer Indian customers the same high-quality fashion that was being manufactured for global giants like Zara, Mango, and Marks & Spencer has today evolved into a profitable, Shark Tank-backed D2C menswear brand. The Bear House, co-founded by Harsh Somaiya, was born out of a belief that Indian consumers deserved better design, fit, and fabric—online. "We thought if an Indian factory can design and manufacture for global brands, why shouldn't Indian customers experience the same premium products and quality? At that time, there was a common perception that good quality products weren't available online. So we decided to change that narrative," said Somaiya. Built on the pillars of great design, fit, and affordability, The Bear House chose a D2C-first approach to maintain control over the entire customer experience. "That means no middlemen, no dilution of brand story," Somaiya explained. "This helped us build loyalty and get instant feedback, which shaped everything from fabric choices to fits." The brand's breakout success was its innovative take on flannel shirts—traditionally warm and heavy—which they re-engineered using lightweight 100% cotton to suit India's climate. "Our flannels have been a bestseller since day one and still contribute to 40% of our shirts revenue," shared Somaiya. With 85% of its sales coming from marketplaces like Myntra, Amazon, and Flipkart, the brand has built a strong digital footprint across over 20,000 pincodes and has a loyal customer base of 20 lakh. It has also stepped into offline retail with stores in Bengaluru and Hyderabad, and is eyeing 10–15 more stores by FY 2025–26. Quick commerce, though a non-traditional fit for fashion, is another frontier the brand is testing. "We've made select collections available on Zepto as a strategic experiment and are noticing good results," said Somaiya. "We're confident that quick commerce fashion will be essential going forward." Internationally, The Bear House has begun its foray into the Middle East and is exploring further global expansion. Closer home, tech-enabled personalisation and new lifestyle categories are on the roadmap. "From bootstrapping to now building a brand with depth, it's been incredibly fulfilling," reflected Somaiya. "At the heart of it, we believe today's men don't just want clothes—they want brands with soul." Facts:
Yahoo
an hour ago
- Yahoo
Smuggler stopped with lizards, tarantulas, possums, authorities say
Indian customs officers made the latest "significant" seizure of endangered wildlife from a passenger arriving from Thailand, a government statement said: nearly 100 creatures including lizards, sunbirds and tree-climbing possums. Customs officers said the passenger, who was also carrying two tarantula spiders and tortoises, had "exhibited signs of nervousness" on arrival at India's financial capital Mumbai. The seizure comes after a passenger was stopped smuggling dozens of venomous vipers, also arriving from Thailand, earlier in June. They included 44 Indonesian pit vipers and were "concealed in checked-in baggage," Mumbai Customs said in a statement. The wildlife in the latest seizure included iguanas, as well as a kinkajou or honey bear -- a small raccoon-like animal from Mexico's rainforests -- along with six "sugar gliders" — a gliding possum found in Australia. Photographs released by the customs unit showed the six sugar gliders huddled together in a basket, as well as a box crammed with lizards. "In a significant operation, customs officers ... intercepted an Indian national ... leading to the seizure of multiple live and deceased wildlife species, some of which are protected under wildlife protection laws," the Ministry of Finance said in a statement late Monday. Disturbing smuggling trend Wildlife trade monitor TRAFFIC, which battles the smuggling of wild animals and plants, on Tuesday warned of a "very troubling" trend in trafficking driven by the exotic pet trade. More than 7,000 animals, dead and alive, have been seized along the Thailand-India air route in the last 3-and-a-half years, it said. Customs officers at Mumbai airport are more used to seizing smuggled gold, cash or cannabis -- but instances of wildlife seizure have seen a gradual rise recently. Customs officers seized dozens of snakes and several turtles from an Indian national flying from Thailand earlier in June. Among them were several spider-tailed horned vipers, a venomous species only described by scientists in 2006 and classified as "near-threatened" by the International Union for the Conservation of Nature (IUCN). TRAFFIC said its analysis showed that while most cases involve animals smuggled out of Thailand, more than 80 percent of interceptions happened in India. "The almost-weekly discoveries and diversity of wildlife en route to India is very troubling," said TRAFFIC's Southeast Asia director Kanitha Krishnasamy. Many of those captured were alive, which "shows that the clamor for exotic pets is driving the trade," she added. In February, customs officials at Mumbai airport also stopped a smuggler with five Siamang gibbons, a small ape native to the forests of Indonesia, Malaysia, and Thailand. Those small creatures, listed as endangered by the IUCN, were "ingeniously concealed" in a plastic crate placed inside the passenger's trolley bag, customs officers said. In November, authorities found a passenger carrying a wriggling live cargo of 12 turtles. Australian reporter covering Los Angeles protests shot with rubber bullet by police officer Kristi Noem says "we are not going to let a repeat of 2020 happen" amid L.A. crackdown LAPD chief speaks out about deployment of military forces to anti-ICE protests
Yahoo
an hour ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
